GemVax
Financials
Valuation Metrics
GemVax's Market Cap is ₩4575B. At end of 2025 it was ₩1.3T. Ranked #496 of 2,421 in KR market (top 20%), #187 of 1,640 on KOSDAQ (top 11%), #64 of 214 in Semiconductors & Semiconductor Equipment (top 30%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 457.53B KRW | KR#496/2,421 Sec#64/214 |
| Revenue | 85.10B KRW | KR#1,513/2,421 Sec#130/214 |
| Net Income | -12.23B KRW | KR—/2,421 Sec—/214 |
| Total Assets | 163.11B KRW | KR#1,447/2,421 Sec#127/214 |
| Net Assets | 73.92B KRW | KR#1,637/2,421 Sec#141/214 |
| Employees | 199 | KR#1,112/2,421 Sec#101/214 |
| Value | ||
| P/B | 6.19x | KR#2,284/2,421 Sec#189/214 |
| P/S | 5.38x | KR#2,162/2,421 Sec#176/214 |
| EV/EBITDA | 60.65x | KR#1,392/2,421 Sec#114/214 |
| FCF Yield | 0.02% | KR#1,220/2,421 Sec#102/214 |
| Profitability | ||
| ROE | -16.54% | KR#2,051/2,421 Sec#181/214 |
| ROA | -7.50% | KR#2,037/2,421 Sec#177/214 |
| Op. Margin | 9.97% | KR#522/2,421 Sec#68/214 |
| Revenue Growth | 24.42% | KR#464/2,421 Sec#77/214 |
| Financial Health | ||
| Debt Ratio | 120.66% | KR#1,720/2,421 Sec#166/214 |
| Total Debt | 75.66B KRW | KR#833/2,421 Sec#55/214 |
| FCF | 111.3M KRW | KR#1,216/2,421 Sec#101/214 |
| Cash | 18.64B KRW | KR#1,285/2,421 Sec#126/214 |
| Current Ratio | 1.08x | KR#1,628/2,421 Sec#154/214 |
| Net Debt/EBITDA | 6.72x | KR#1,112/2,421 Sec#107/214 |
| Performance | ||
| 1Y Return | -80.16% | KR#2,354/2,421 Sec#213/214 |
| 1M Return | -5.27% | KR#1,815/2,421 Sec#171/214 |
| From 52W High | -83.51% | KR#2,374/2,421 Sec#213/214 |
| 1Y MDD | -84.50% | KR#2,355/2,421 Sec#211/214 |
| Trading | ||
| Volume | 101,600 shares | KR#771/2,421 Sec#104/214 |
| Trading Value | 1.03B KRW | KR#710/2,421 Sec#105/214 |
| Foreign Own. | 7.01% | KR#639/2,421 Sec#72/214 |
| Per Share | ||
| EPS | -269 KRW | KR—/2,421 Sec—/214 |
| BPS | 1,625 KRW | KR#2,157/2,421 Sec#192/214 |
Company Info
GemVax, established in 1998 for the manufacturing and sale of Coating Resin and filters, was listed on the KOSDAQ market in 2005. In its environmental pollution control division, the company specializes in localizing Chemical Filters for semiconductor and display applications, as well as providing air pollution prevention equipment. The bio division conducts clinical trials for diseases such as Alzheimer's using GV1001, simultaneously focusing on expanding overseas demand and researching next-generation peptide drugs. GemVax is headquartered in Seongnam City, Gyeonggi-do.